|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis显示文摘AIM: To compare endoscopic submucosal dissection(ESD) and endoscopic mucosal resection(EMR) for early gastric cancer(EGC).METHODS: Computerized bibliographic search was performed on PubMed/Medline, Embase, Google Schol-ar and Cochrane library databases. Quality of each included study was assessed according to current Co-chrane guidelines. Primary endpoints were en bloc re-section rate and histologically complete resection rate. Secondary endpoints were length of procedure, post-treatment bleeding, post-procedural perforation and re-currence rate. Comparisons between the two treatment groups across all the included studies were performed by using Mantel-Haenszel test for fixed-effects mod-els(in case of low heterogeneity) or DerSimonian and Laird test for random-effects models(in case of high heterogeneity).RESULTS: Ten retrospective studies(8 full text and 2 abstracts) were included in the meta-analysis. Overall data on 4328 lesions, 1916 in the ESD and 2412 in the EMR group were pooled and analyzed. The mean operation time was longer for ESD than for EMR(stan-dardized mean difference 1.73, 95%CI: 0.52-2.95, P =0.005) and the 'en bloc ' and histological complete re-section rates were significantly higher in the ESD group [OR = 9.69(95%CI: 7.74-12.13), P < 0.001 and OR = 5.66,(95%CI: 2.92-10.96), P < 0.001, respectively]. As a consequence of its greater radicality, ESD provided lower recurrence rate [OR = 0.09,(95%CI: 0.05-0.17), P < 0.001]. Among complications, perforation rate was significantly higher after ESD [OR = 4.67,(95%CI, 2.77-7.87), P < 0.001] whereas the bleeding incidences did not differ between the two techniques [OR = 1.49(0.6-3.71), P = 0.39].CONCLUSION: In the endoscopic therapy of EGC, ESD showed a superior efficacy but higher complication rate with respect to EMR. | Antonio Facciorusso Matteo Antonino Marianna Di Maso Nicola Muscatiello | 2014 | World Journal of Gastrointestinal Endoscopy2014，6，11： | 50 |
| 2 | Transarterial chemoembolization:Evidences from the literature and applications in hepatocellular carcinoma patients显示文摘Transarterial chemoembolization(TACE) is the current standard of care for patients with large or multinodular hepatocellular carcinoma(HCC), preserved liver function, absence of cancer-related symptoms and no evidence of vascular invasion or extrahepatic spread(i.e., those classified as intermediate stage according to the Barcelona Clinic Liver Cancer staging system). The rationale for TACE is that the intra-arterial injection of a chemotherapeutic drug such as doxorubicin or cisplatin followed by embolization of the blood vessel will result in a strong cytotoxic effect enhanced by ischemia. However, TACE is a very heterogeneous operative technique and varies in terms of chemotherapeutic agents, treatment devices and schedule. In order to overcome the major drawbacks of conventional TACE(c TACE), non-resorbable drug-eluting beads(DEBs) loaded with cytotoxic drugs have been developed. DEBs are able to slowly release the drug upon injection and increase the intensity and duration of ischemia while enhancing the drug delivery to the tumor. Unfortunately, despite the theoretical advantages of this new device and the promising results of the pivotal studies, definitive data in favor of its superiority over c TACE are still lacking. The recommendation for TACE as the standard-of-care for intermediate-stage HCC is based on the demonstration of improved survival compared with best supportive care or suboptimal therapies in a meta-analysis of six randomized controlled trials, but other therapeutic options(namely, surgery and radioembolization) proved competitive in selected subsets of intermediate HCC patients. Other potential fields of application of TACE in hepato-oncology are the pre-transplant setting(as downstaging/bridging treatment) and the early stage(in patients unsuitable to curative therapy). The potential of TACE in selectedadvanced patients with segmental portal vein thrombosis and preserved liver function deserves further reports. | Antonio Facciorusso Raffaele Licinio Nicola Muscatiello Alfredo Di Leo Michele Barone | 2015 | World Journal of Hepatology2015，7，16： | 25 |
| 3 | Local ablative treatments for hepatocellular carcinoma:An updated review显示文摘Ablative treatments currently represent the first-line option for the treatment of early stage unresectable hepatocellular carcinoma(HCC).Furthermore,they are effective as bridging/downstaging therapies before orthotopic liver transplantation.Contraindications based on size,number,and location of nodules are quite variable in literature and strictly dependent on local expertise.Among ablative therapies,radiofrequency ablation(RFA) has gained a pivotal role due to its efficacy,with a reported 5-year survival rate of 40%-70%,and safety.Although survival outcomes are similar to percutaneous ethanol injection,the lower local recurrence rate stands for a wider application of RFA in hepato-oncology.Moreover,RFA seems to be even more cost-effective than liver resection for very early HCC(single nodule ≤ 2 cm) and in the presence of two or three nodules ≤ 3 cm.There is increasing evidence that combining RFA to transarterial chemoembolization may increase the therapeutic benefit in larger HCCs without increasing the major complication rate,but more robust prospective data is still needed to validate these pivotal findings.Among other thermal treatments,microwave ablation(MWA) uses high frequency electromagnetic energy to induce tissue death via coagulation necrosis.In comparison to RFA,MWA has several theoretical advantages such as a broader zone of active heating,higher temperatures within the targeted area in a shorter treatment time and the lack of heatsink effect.The safety concerns raised on the risks of this procedure,due to the broader and less predictable necrosis areas,have been recently overcome.However,whether MWA ability to generate a larger ablation zone will translate into a survival gain remains unknown.Other treatments,such as high-intensity focused ultrasound ablation,laser ablation,and cryoablation,are less investigated but showed promising results in early HCC patients and could be a valuable therapeutic option in the next future. | Antonio Facciorusso Gaetano Serviddio Nicola Muscatiello | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，4： | 23 |
| 4 | Non-polypoid colorectal neoplasms:Classification,therapy and follow-up显示文摘In the last years,an increasing interest has been raised on non-polypoid colorectal tumors(NPT) and in particular on large flat neoplastic lesions beyond 10 mm tending to grow laterally,called laterally spreading tumors(LST).LSTs and large sessile polyps have a greater frequency of high-grade dysplasia and local invasiveness as compared to pedunculated lesions of the same size and usually represent a technical challenge for the endoscopist in terms of either diagnosis and resection.According to the Paris classification,NPTs are distinguished in slightly elevated(0-Ⅱa,less than 2.5 mm),flat(0-Ⅱb) or slightly depressed(0-Ⅱc).NPTs are usually flat or slightly elevated and tend to spread laterally while in case of depressed lesions,cell proliferation growth progresses in depth in the colonic wall,thus leading to an increased risk of submucosal invasion(SMI) even for smaller neoplasms.NPTs may be frequently missed by inexperienced endoscopists,thus a careful training and precise assessment of all suspected mucosal areas should be performed.Chromoendoscopy or,if possible,narrow-band imaging technique should be considered for the estimation of SMI risk of NPTs,and the characterization of pit pattern and vascular pattern may be useful to predict the risk of SMI and,therefore,to guide the therapeutic decision.Lesions suitable to endoscopic resection are those confined to the mucosa(or superficial layer of submucosa in selected cases) whereas deeper invasion makes endoscopic therapy infeasible.Endoscopic mucosal resection(EMR,piecemeal for LSTs > 20 mm,en bloc for smaller neoplasms) remains the first-line therapy for NPTs,whereas endoscopic submucosal dissection in high-volume centers or surgery should be considered for large LSTs for which en bloc resection is mandatory and cannot be achieved by means of EMR.After piecemeal EMR,follow-up colonoscopy should be performed at 3 mo to assess resection completeness.In case of en bloc resection,surveillance colonoscopy should be scheduled at 3 years for adenomatous lesions ≥ 1 cm,or in presence of villous features or high-grade dysplasia patients(regardless of the size),while less intensive surveillance(colonoscopy at 5-10 years) is needed in case of single(or two) NPT < 1 cm presenting tubular features or low-grade dysplasia at histology. | Antonio Facciorusso Matteo Antonino Marianna Di Maso Michele Barone Nicola Muscatiello | 2015 | World Journal of Gastroenterology2015，21，17： | 20 |
| 5 | Development and validation of a risk score for advanced colorectal adenoma recurrence after endoscopic resection显示文摘AIM: To develop and validate a risk score for advanced colorectal adenoma(ACA) recurrence after endoscopic polypectomy.METHODS: Out of 3360 patients who underwent colon polypectomy at University of Foggia between 2004 and 2008, data of 843 patients with 1155 ACAs was retrospectively reviewed. Surveillance intervals were scheduled by guidelines at 3 years and primary endpoint was considered 3-year ACA recurrence. Baseline clinical parameters and the main features of ACAs were entered into a Cox regression analysis and variables with P < 0.05 in the univariate analysis were then tested as candidate variables into a stepwise Cox regression model(conditional backward selection). The regression coefficients of the Cox regression model were multiplied by 2 and rounded in order to obtain easy to use point numbers facilitating the calculation of the score. To avoid overoptimistic results due to model fitting and evaluation in the same dataset, we performed an internal 10-fold cross-validation by means of bootstrap sampling. RESULTS: Median lesion size was 16 mm(12-23) while median number of adenomas was 2.5(1-3), whereof the number of ACAs was 1.5(1-2). At 3 years after polypectomy, recurrence was observed in 229 ACAs(19.8%), of which 157(13.5%) were metachronous neoplasms and 72(6.2%) local recurrences. Multivariate analysis, after exclusion of the variable 'type of resection' due to its collinearity with other predictive factors, confirmed lesion size, number of ACAs and grade of dysplasia as significantly associated to the primary outcome. The score was then built by multiplying the regression coefficients times 2 and the cut-off point 5 was selected by means of a Receiver Operating Characteristic curve analysis. In particular, 248 patients with 365 ACAs fell in the higher-risk group(score ≥ 5) where 3-year recurrence was detected in 174 ACAs(47.6%) whereas the remaining 595 patients with 690 ACAs were included in the low-risk group(score < 5) where 3-year recurrence rate was 7.9%(55/690 ACAs). Area under the curve of the model was 0.81(0.72-0.86) with an overall classification error rate of 0.09. The model was finally validated by means of 10-fold cross validation.CONCLUSION: Our study provides support for the use of a novel risk score as a clinical predictor of ACA recurrence after colon polypectomy. | Antonio Facciorusso Marianna Di Maso Gaetano Serviddio Gianluigi Vendemiale Nicola Muscatiello | 2016 | World Journal of Gastroenterology2016，22，26： | 8 |
| 6 | Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients:A systematic review and metaanalysis显示文摘AIM: To compare the efficacy and safety of yttrium-90 radioembolization(Y90RE) and transarterial chemoembolization(TACE) in hepatocellular carcinoma patients. METHODS: Bibliographic research was conducted on main scientific databases. When there was no statistically significant heterogeneity, pooled effects were calculated using a fixed-effects model by means of Mantel-Haenszel test, otherwise, a random-effects model was used with Der Simonian and Laird test. Summary estimates were expressed in terms of odds ratios(ORs) and 95%CI. The probability of publication bias was assessed using funnel plots and with Begg and Mazumdar's test. Sensitivity analysis was finally conducted using the method of excluding extreme data.RESULTS: A total of 10 studies were analyzed, of which 2 randomized controlled trials. Survival rate(SR) assessed at 1 year showed an absolute similarity between the two treatment groups(OR = 1.01, 95%CI: 0.78-1.31, P = 0.93). As long as time elapsed since the treatment, ORs for survival rate tended to significantly increase, thus meaning better long-term outcomes in patients who underwent Y90RE(2-year SR: OR = 1.43, 1.08-1.89, P = 0.01; 3-year SR: OR = 1.48, 1.03-2.13, P = 0.04). Meta-analysis of plotted hazard ratios(HRs) determined a non-significant overall estimate in favor of Y90RE(HR = 0.91, 0.80-1.04, P = 0.16). Y90 RE showed a statistically significant benefit as compared to TACE in terms of higher progression-free survival rateassessed at 1 year(OR = 1.67; 95%CI: 1.10-2.55; P = 0.02). Pooled analyses do not revealed a statistically significant increase in OR for tumor objective responses after Y90 RE with respect to TACE(OR = 1.22, 95%CI: 0.69-2.16, P = 0.50). A non-significant trend in favor of Y90 RE was observed according to adverse event rate(OR = 0.70, 0.38-1.30, P = 0.26).CONCLUSION: Our meta-analysis reveals that Y90 RE and TACE show similar effects in terms of survival, response rate and safety profile, although tumor progression is delayed after radioembolization. | Antonio Facciorusso Gaetano Serviddio Nicola Muscatiello | 2016 | World Journal of Hepatology2016，8，18： | 5 |
| 7 | Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases显示文摘AIM: To test the correlation between lymphocyte-tomonocyte ratio(LMR) and survival after radiofrequency ablation(RFA) for colorectal liver metastasis(CLMs). METHODS: From July 2003 to Feb 2012, 127 consecutive patients with 193 histologically-proven unresectable CLMs were treated with percutaneous RFA at the University of Foggia. All patients had undergone primary colorectal tumor resection before RFA and received systemic chemotherapy. LMR was calculated by dividing lymphocyte count by monocyte count assessed at baseline. Treatment-related toxicity was defined as any adverse events occurred within 4 wk after the procedure. Overall survival(OS) and time to recurrence(TTR) were estimated from the date of RFA by Kaplan-Meier with plots and median(95%CI). The inferential analysis for time to event data was conducted using the Cox univariate and multivariate regression model to estimate hazard ratios(HR) and 95%CI. Statistically significant variables from the univariate Cox analysis were considered for the multivariate models.RESULTS: Median age was 66 years(range 38-88) and patients were prevalently male(69.2%). Median LMR was 4.38%(0.79-88) whereas median number of nodules was 2(1-3) with a median maximum diameter of 27 mm(10-45). Median OS was 38 mo(34-53) and survival rate(SR) was 89.4%, 40.4% and 33.3% at 1, 4 and 5 years respectively in the whole cohort. Running log-rank test analysis found 3.96% as the most significant prognostic cut-off point for LMR and stratifying the study population by this LMR value median OS resulted 55 mo(37-69) in patients with LMR > 3.96% and 34(26-39) mo in patients with LMR ≤ 3.96%(HR = 0.53, 0.34-0.85, P = 0.007). Nodule size and LMR were the only significant predictors for OS in multivariate analysis. Median TTR was 29 mo(22-35) with a recurrence-free survival(RFS) rate of 72.6%, 32.1% and 21.8% at 1, 4 and 5 years, respectively in the whole study group. Nodule size and LMR were confirmed as significant prognostic factors for TTR in multivariate Cox regression. TTR, when stratified by LMR, was 35 mo(28-57) in the group > 3.96% and 25 mo(18-30) in the group ≤ 3.96%(P = 0.02).CONCLUSION: Our study provides support for the use of LMR as a novel predictor of outcome for CLM patients. | Antonio Facciorusso Valentina Del Prete Nicola Crucinio Gaetano Serviddio Gianluigi Vendemiale Nicola Muscatiello | 2016 | World Journal of Gastroenterology2016，22，16： | 4 |
| 8 | Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients显示文摘 | Antonio Facciorusso Valentina Del Prete Nicola Crucinio Nicola Muscatiello Brian I Carr Alfredo Di Leo Michele Barone | 2015 | J Gastroenterol Hepatol2015，，11： | 2 |
| 9 | Polidocanol injection decreases the bleeding rate after colon polypectomy: a propensity score analysis显示文摘 | Antonio Facciorusso Marianna Di Maso Matteo Antonino Valentina Del Prete Carmine Panella Michele Barone Nicola Muscatiello | 2015 | Gastrointestinal Endoscopy2015，，2： | 2 |
| 10 | Dermal tolerance and effect on skin hydration of a new ethanol-based hand gel显示文摘 | Kampf G Muscatiello M Hantschel D | 2002 | J Hosp Infect2002，52，4： | 2 |
| 11 | CTFA’S preservation guidelines: a historicalperspective and review 显示文摘 | M J Muscatiello | 1993 | Cosmetics & toiletries1993，108，： | 1 |
| 12 | CTFAs preservation guidelines: a histories perspective and review显示文摘 | MUSCATIELLO M J | 1993 | C&T1993，108，： | 1 |
| 13 | Statins decrease the risk of acute pancreatitis after endoscopic ultrasound fine-needle aspiration of pancreatic cysts显示文摘Background: Basic and clinical studies suggest that statins may prevent and even ameliorate acute pan- creatitis. The present study was to evaluate whether statin decreases the risk of acute pancreatitis in patients undergoing endoscopic ultrasound-guided ne-needle aspiration of pancreatic cysts. Methods: Out of 456 patients with pancreatic cysts referred to our center between 2006 and 2018, 365 were nally included in analyses: 86 were treated with statins and 279 were not at the time of endo- scopic ultrasound ne-needle aspiration. We compared the acute pancreatitis incidence between the two groups, and we also compared other complications such as bleeding and infections. Results: Median age was 64 years [interquartile range (IQR) 62 69] and median cyst size was 24mm (IQR, 21 29). The most frequent histology was intraductal papillary mucinous neoplasm (45.3% and 42.3% in the two groups, respectively;P =0.98). All 13 patients experiencing post-endoscopic ultrasound acute pancreatitis were from the control group (4.7%), of which 3 were classi ed as severe pancreatitis. None of statin users developed post-procedural acute pancreatitis (odds ratio: 0.15;95% con dence interval: 0.03 0.98;P=0.03). No difference was registered with regard to severe pancreatitis and other complications. Conclusions: Statins exert a bene cial role in preventing acute pancreatitis in patients with pancreatic cysts undergoing endoscopic ultrasound-guided ne-needle aspiration. If con rmed in prospective trials, our ndings may pave the way to an extensive use of statins as prophylactic agents in pancreatic inter- ventional endoscopy. | Antonio Facciorusso Vincenzo Rosario Buccino Valentina Del Prete Matteo Antonino Antonella Contaldo Nicola Muscatiello | 2020 | Hepatobiliary & Pancreatic Diseases International2020，19，1： | 1 |
| 14 | CTFAs preservation guidelines: a histories perspective and review 显示文摘 | M J Muscatiello | 1993 | C & T1993，108，： | 1 |
| 15 | CTFA'S preservation guidelines:a historical perspective and review显示文摘 | M J Muscatiello | 1993 | Cosmetics & Toiletries1993，108，： | 1 |
| 16 | CTFA's preservation guidelines: a historical perspective and review显示文摘 | MUSCATIELLO M J | 1993 | Cosmetics and Toilet- ries1993，108，10： | 1 |
| 17 | CTFA' s preservation guidelines:A historical per- spective and review 显示文摘 | MUSCATIELLO M J | 1993 | Cometics & Toiletries1993，108，： | 1 |
| 18 | CTFAs preservation guidelines: a his- tories perspective and review显示文摘 | MUSCATIELLO M J | 1993 | Cosmetics and Toiletries1993，108，： | 1 |
| 19 | Combination therapy with sorafenib and radioffequency ablation for hepatocellular carcino- ma: a glimmer of light after the storm trial 显示文摘 | Facciorusso A Muscatiello N Di Leo A | 2015 | Am J Gastroenterol2015，110，5： | 1 |
| 20 | Treatment of a pan- creatic endocrine tumor by ethanol injection guided by endoscopic ultrasound显示文摘 | Muscatiello N Salcuni A Macarini L | 2008 | Endoscopy2008，402，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员